Pre-Made Asfotase Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Enzyme fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research

Pre-Made Asfotase Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Enzyme fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Asfotase alfa, sold under the brand name Strensiq, is a medication used in the treatment of people with perinatal/infantile- and juvenile-onset hypophosphatasia.[3][4][5][6]

Asfotase alfa is an enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP). Hypophosphatasia is caused by a genetic defect of tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme that plays a role in bone mineralization. Asfotase alfa is a recombinant glycoprotein that contains the catalytic domain (the active site) of TNSALP. It is therefore used as an enzyme replacement therapy

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-740-1mg	1mg	3090
GMP-Bios-INN-740-10mg	10mg	Inquiry
GMP-Bios-INN-740-100mg	100mg	Inquiry
GMP-Bios-INN-740-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Asfotase Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Enzyme fused with human IGHG1 Fc (Fragment constant)
INN Name	Asfotase Alfa
Target	Enzyme
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [ALPL (alkaline phosphatase, TNSALP, tissue non-specific alkaline phosphatase) 18- 502]2 - IGHG1 Fc (Fragment constant) - Asp-Ile- deca-aspartate
VD LC	Fusion - [ALPL (alkaline phosphatase, TNSALP, tissue non-specific alkaline phosphatase) 18- 502]2 - IGHG1 Fc (Fragment constant) - Asp-Ile- deca-aspartate
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Alexion Pharmaceuticals Inc. (New Haven CT USA) / Enobia pharma (Cambridge MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0